Agencies rock for a good cause at Pharmapalooza

Share this article:
Agencies rock for a good cause at Pharmapalooza
Agencies rock for a good cause at Pharmapalooza

Corbett Accel Healthcare Group can add music to its list of creative achievements after its Chicago office triumphed in last night's Pharmapalooza “battle of the bands” contest at B.B. King's Blues Club & Grill in New York City.

Heavy Medical — comprising Jeff Holtorf (drums), Terry Barich (harmonica, vocals), Brian Catral (keyboards, vocals), Jack Cunningham (bass, vocals), Joe Mason (theremin, vocals), Matt Pearl (guitar, vocals) Nicole Stachura (percussion, vocals) and Kelly Christiansen (percussion, vocals) — rocked a sell-out crowd of 750 vociferous industry colleagues and supporters.

In second place was Late Night Car Service (a.k.a. Sudler & Hennessey) which got the vote from MM&M's unofficial panel in attendance. But the real winners of the charity event, which was conceived and organized by New York-based Cline Davis & Mann, was the Children's Hospital at Montefiore, for whom more than $110,000 was raised.

Other contestants were May Cause Nausea (Ogilvy Healthworld), Grand pRx (GSW Worldwide), Pharmatopia (Corbett Accel New York), Mr. Tiny's Revenge (Grey Healthcare Group), SIDEFX (Regan Campbell Ward • McCann), BANDRx (AgencyRx) and Black Box Warning (Harrison & Star). CDM had set the tone with an impressive opening set from its 21-member ensemble, Uncle Funkus.

 

Share this article:

Email Newsletters

More in News

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.